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The G-protein bile acid receptor 1 (GPBAR1) has emerged in the last decade as prominent target for 
the treatment of metabolic and inflammatory diseases including type 2 diabetes, obesity, and non-
alcoholic steatohepatitis. To date numerous bile acid derivatives have been identified as GPBAR1 
agonists, however their clinical application is hampered by the lack of selectivity toward the other 
bile acid receptors. Therefore, non-steroidal GPBAR1 ligands able to selectively activate the receptor 
are urgently needed. With this aim, we here designed, synthesized and biologically evaluated 
((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl) urea derivatives as novel potent GPBAR1 agonists. Particularly, 
compounds 9 and 10 induce the mRNA expression of the GPBAR1 target gene pro-glucagon and show 
high selectivity over the other bile acid receptors FXR, LXRα, LXRβ and PXR, and the related receptors 
PPARα and PPARγ. Computational studies elucidated the binding mode of 10 to GPBAR1, providing 
important structural insights for the design of non-steroidal GPBAR1 agonists. The pharmacokinetic 
properties of 9 and 10 suggest that the ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureydil scaffold might be 
exploited to achieve effective drug candidates to treat GPBAR1 related disorders.
Bile acids (BAs) are amphipathic molecules synthesized from cholesterol in the liver and stored in the gallbladder, 
from where they are released during digestion to emulsify lipid-soluble nutrients. In addition to their role in diet 
lipids absorption, bile acids act as signaling molecules involved in the systemic regulation of multiple metabolic 
pathways. Such endocrine functions are mainly exerted through their interaction with nuclear hormone recep-
tors (NHRs) and cell membrane receptors1. Among NRs, the farnesoid X receptor (FXR) plays a major role2–4. 
This receptor is highly expressed in the liver, intestine, kidney, adrenal glands and adipose tissue representing 
a major regulator of bile acid homeostasis5 and glucose, triglyceride and cholesterol metabolism6–9. The main 
example of bile acid cell membrane receptor is the G-protein coupled bile acid receptor 1 (GPBAR1, also known 
as TGR5 or M-BAR)10,11. GPBAR1 is expressed in the brown adipose tissue, muscle, liver, intestine, gallbladder, 
immune system cells and selected areas of the central nervous system regulating multiple functions1. GPBAR1 
activation in intestinal enteroendocrine L cells stimulates the transcription of the proglucagon gene expression 
and the secretion of the incretin GLP-1, thus lowering blood glucose and insulin levels while increasing insulin 
sensitivity12–14. In brown adipose tissue and muscle, GPBAR1 locally stimulates thyroid hormone-mediated ther-
mogenesis, thereby enhancing energy expenditure15. In addition, activation of GPBAR1 in macrophages reduces 
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the release of pro-inflammatory cytokines, producing in turn anti-inflammatory effects16–18. For all these reasons, 
the development of GPBAR1 agonists represents an intriguing strategy for the treatment of metabolic disorders 
like type II diabetes, obesity, inflammatory diseases and some types of cancer9,19,20. Starting from the evidence 
that FXR and GPBAR1 regulate overlapping metabolic functions21,22 many efforts were spent for the identifi-
cation of dual GPBAR1/FXR agonists23–25. Nevertheless, these compounds show unwanted side effects due to 
over-activation of the two receptors26,27. As a consequence, most recent studies have focused on the identification 
of selective ligands towards either FXR or GPBAR1. We and other groups have contributed to this field report-
ing a number of BA derivatives as selective agonists of these receptors28–34. Nevertheless, the clinical use of BA 
derivatives is hampered by a number of limitations. In particular, they are promiscuous ligands able to activate 
simultaneously different bile acid receptors such as GPBAR1, FXR, the pregnane X receptor (PXR)35 and the liver 
X receptors (LXR α and β)36,37, therefore showing a number of off-target effects. Furthermore, BA derivatives are 
intrinsically endowed with detergent-like properties forming cytotoxic micellar aggregates20,38. These issues have 
prompted medicinal chemists to design non-BA modulators of these receptors. In particular, the chemical struc-
ture of non-BA ligands lacks of the steroidal cycle that is responsible for the promiscuous binding affinity of the 
BA derivatives to the different BAs receptors. The few reported non-steroidal GPBAR1 ligands show promising 
results against type 2 diabetes and other GPBAR1 related disorders39–43. Therefore, the discovery of novel selective 
non-steroidal GPBAR1 agonists has become in great demand. With this aim, we performed a structure-based 
drug design study, using the 3D model of GPBAR1 that we have recently reported24, which led to the identifica-
tion of a new series of non-steroidal selective GPBAR1 agonists. These compounds have a ((1,2,4-oxadiazol-5-yl)
pyrrolidin-3-yl)ureidyl core that represents a new chemical scaffold for GPBAR1 ligands if compared with the 
previously reported compounds9,20,22. Here, we show that this scaffold is crucial for the binding interaction to 
the orthosteric site residues of the receptor. Using transactivation assays, we demonstrate the ability of the new 
series of compounds to activate selectively GPBAR1 over the other BAs receptors as FXR, LXRα, LXRβ and PXR, 
and the related receptors PPARα and PPARγ. The most potent derivatives, 9 and 10, demonstrate to induce the 
expression of mRNA of the GPBAR1 target gene pro-glucagon, with compound 10 showing the same efficacy 
of the endogenous agonist TLCA10,11. We have elucidated the binding mode of the most potent compound of 
the series (10) combining docking calculations and molecular dynamics simulations, showing that the residues 
Glu169, Asn93 and Tyr240 play a leading role in the ligand recognition. While the same residues are known to 
be involved in the binding of BA derivatives33,34,44,45, this is an unprecedented structural insight for non-steroidal 
GPBAR1 agonists that paves the way to following lead-optimization and drug design studies. The high GPBAR1 
activity efficacy and the optimal pharmacokinetic profile of the new compounds place the ((1,2,4-oxadiazol-5-yl)
pyrrolidin-3-yl)ureidyl scaffold in an optimal fashion for further investigations to achieve drug candidates to treat 
GPBAR1-related metabolic disorders.
Results
Design and Synthesis. In the very first stage of our research, we performed a docking-based vir-
tual screening (VS) study, using the 3D model of GPBAR1 that we have recently reported24, to identify new 
potential GPBAR1 ligands. This procedure led to the identification of eleven compounds (Compounds A-L in 
Supplementary Fig. S1) that were purchased from AnalytiCon (http://www.ac-discovery.com). These compounds 
underwent a thorough characterization of their purity and chemical structures. This investigation showed that 
the structure of one of the purchased ligands did not correspond to that declared by the vendor and evaluated by 
our calculations. Specifically, NMR spectroscopy studies revealed the presence of a meta-CF3 phenyl ring instead 
of the para-CF3-phenyl moiety (see Supplementary Figs S2 and S3) in compound F. This discovery prompted 
us to synthesize ab initio the para-CF3 phenyl analogue (Compound F from VS, Fig. 1). Unfortunately, trans-
activation assay on GPBAR1 revealed that none of compounds A-L from VS was endowed with remarkable 
activity when compared to TLCA, the endogenous GPBAR1 agonist (Supplementary Fig. S4). Nevertheless, we 
noticed that compound F as well as several of the other identified putative GPBAR1 ligands from VS share the 
Figure 1. Compound F from VS and derivatives 1–14 identified in this study as a new chemotype of GPBAR1 
agonists.
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3,5-disubstituted 1,2,4-oxadiazole moiety (compounds F, G, H, J), which resembles previously reported GPBAR1 
agonists20. Furthermore, the 1,2,4-oxadiazole ring is a common privileged scaffold that has emerged as a core 
structural unit of various bioactive compounds. This heterocycle can indeed act as bioisostere for both amide 
and carboxylic acid  moieties, improving the pharmacokinetic and pharmacodynamic profile, enhancing selec-
tivity, fixing conformations and modulating polarity of the drug candidates. After the set up of the total synthe-
sis of compound F, we tested using transactivation assays the simplified analogues in our hands (compounds 
1–4 in Fig. 1) including the N-demethylated analogue of compound F, compound 4. The latter showed moder-
ate GPBAR1 agonist activity that prompted us to explore further the chemical space around the (1,2,4-oxadi-
azol-5-yl)pyrrolidin-3-yl scaffold in a lead optimization study. Finally, this process led to the identification of a 
new class of GPBAR1 agonists.
As regards the organic synthesis, 1,2,4-oxadiazoles 1–14 were prepared in a convergent synthesis from ben-
zonitrile 15 and (3R)-hydroxy-Boc-L-proline. Briefly, treatment of 15 with hydroxylamine hydrochloride afforded 
the intermediate amidoxime 16 (quantitative yield), that was coupled with (3R)-hydroxy-Boc-L-proline by using 
(2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent, yielding 
to the formation of compound 17 (60% yield). Mesylation on 17 followed by treatment with NaN3 furnished the 
intermediate 18. The reduction of the azido group with NH4Cl/Zn powder gives the amino derivative 19, as a key 
intermediate in the preparation of compound F and compounds 4–14.
First, treatment of 19 with 4-(trifluoromethyl)phenylisocyanate followed by acid removal of N-protecting 
group afforded compound 4 whose N-methylation by reductive amination furnished compound F in 56% yield 
(Fig. 2). Then treatment of 19 with differentiated isocyanates, followed by acid removal of the N-Boc protecting 
group, afforded compounds 5–14. Finally, for lead fragmentation process, little amounts of intermediates 17, 18 
and 19 have been Boc-deprotected affording compounds 1, 2 and 3 respectively.
Pharmacological Evaluation. The activity of compounds 1–14 on GPBAR1 was evaluated in a luciferase 
reporter assay using HEK-293T cells transfected with GPBAR1. The efficacy of tested compounds (Table 1) was 
measured using taurolithocholic acid (TLCA) as GPBAR1 reference compound10,11. Each compound was tested 
at the concentration of 10 μM and transactivation activity of TLCA on a cAMP responsive element (CRE) (i.e. 
TGR5/GPBAR1) was considered equal to 100%. As shown in Table 1, the efficacy of compounds 1–14 was in 
58–121% range, with compounds 9 (EC50 3.5 μM, 115% efficacy) and 10 (EC50 4.6 μM; 121% efficacy) showing 
the best efficacy/potency match (Table 1 and Fig. 3, panel A). Moreover, the agonism of 9 and 10 was further 
assessed by RT-PCR experiments in which each of two compounds was effective in inducing the expression of 
pro-glucagon mRNA in GLUTag cells, an intestinal endocrine cell line (Fig. 3, panel B). Remarkably, 10 shows the 
same efficacy of TLCA in inducing pro-glucagon mRNA expression. Thus, 9 and 10 (Table 1) turned out to be the 
most promising derivatives considering their low EC50 values and high activity efficacy. To further characterize 
the pharmacological properties of these compounds, we expanded their in vitro profile to common off-targets 
for bile acid receptor ligands. As showed in Fig. 3, panels C–F, 9 and 10 (10 μM) were unable to induce PPARα/
PPARγ, LXRα/LXRβ as well as FXR and PXR transactivation on HepG2 cells.
In vitro pharmacokinetics characterization. In order to assess the drug-likeness of 9 and 10, we evalu-
ated some of their physiochemical properties such as the partition coefficient (clogP), the aqueous solubility and 
the in vitro rat liver microsomal stability (Table 2). Remarkably, 9 and 10 show aqueous solubility of 42 μg/mL 
(110 μM) and 70 µg/mL (198 µM), respectively, and a moderate lipophilicity (9, logD = 1.47; 10, logD = 1.25). 
Figure 2. Preparation of compound F from VS, its simplified derivatives 1–4 and optimized GPBAR1 agonists 
5–14. Reagents and conditions: (a) NH2OH·HCl, K2CO3, CH3OH reflux, quantitative yield; (b) (3R)-hydroxy-
Boc-L-proline, DIPEA, HBTU in DMF, 80 °C, 60%; (c) MsCl, TEA, −10 °C, 2 h, quantitative yield; (d) NaN3 in 
DMSO, 150 °C, 4 h, 75%; (e) NH4Cl, Zn, CH3OH:H2O (1:0.1), 61%; (f) 4-(trifluoromethyl)phenyl isocyanate, 
CH2Cl2, 0 °C, 84%; (g) TFA, 2 h, quantitative yield; (h) HCHO, HCOOH, 80–90 °C overnight, 56%; (i) R2NCO, 
CH2Cl2, 0 °C, 74%.
4Scientific RepoRts |          (2019) 9:2504  | https://doi.org/10.1038/s41598-019-38840-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
Notably, both compounds offer the possibility to improve their solubility and polarity by a salt formation via the 
amine group and, according to Lipinski’s Rule of Five, exhibit a clogP value between 1 and 2, which is favorable for 
orally administered drugs. Finally, 9 and 10 are characterized by a medium clearance (Cl) and a moderate half-life 
(t1/2) (Table 2), with 42% and 40% of 9 and 10 remaining 40 min after treatment, respectively, and both parameters 
are indicative of their good metabolic stability in vitro.
Molecular Modeling. In order to elucidate the binding mode of the newly synthesized derivatives to 
GPBAR1, molecular modeling studies were carried out on the most promising derivative of the series, 10. 
First, molecular docking calculations were performed on 10 in the 3D homology model of GPBAR1, which 
we originally built in 201424 and validated in the following years with a number of successful drug design stud-
ies33,34,46,47. Among the binding modes predicted by docking, only two poses interact with Glu169 of GPBAR1 
(Supplementary Fig. S5), which is known to be involved in the binding of agonists and receptor activation24,44,45. 
Therefore, these two poses were further investigated through more accurate calculations. In particular, each pose 
underwent to 150 ns MD simulations in explicit solvent and membrane not only to fully take into account the 
receptor flexibility and the solvent effect but also to evaluate the energetics and structural stability of the two 
binding modes.
The MD calculations show that only one of the two docking poses is stable over the simulation time, as shown 
by the values of the root mean square deviation (rmsd) computed for the ligand heavy atoms (Supplementary 
Fig. S6). In the energetically most stable pose (Fig. 4A), the ligand pyrrolidinyl ring engages a salt bridge 
with the Glu169 side chain on transmembrane helix (TM) 5 and a H-bond with Asn93 on TM3, while the 
phenyl-oxadiazolyl moiety deepens in the lipophilic pocket formed by the side chains of residues such as Leu85, 
Phe96, Leu100, Leu173, Leu174, and Trp237 and Tyr240. On the other side, the ligand cyclohexyl ring occupies 
N° Compound Efficacy (% vs TLCA)
1 72%
2 58%
3 74%
R2
4 4-CF3-Ph 68%
5 Ph 79%
6 4-Me-Ph 65%
7 4-OMe 81%
8 4-F 96%
9 4-Cl 115%
10 C6H11 121%
11 CH2Ph 78%
12 4-OPh-Ph 85%
13 Naphtyl 95%
14 Biphenyl 95%
Table 1. Efficacy data resulted from comparison of the maximal transactivation of CRE (cAMP responsive 
element) caused by each compound (10 μM) with that of TLCA (10 μM). Data are calculated from the same 
experiment conducted in triplicate.
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the small hydrophobic cleft defined by Leu68 and Leu71 on TM2 and Phe96 on TM3, which are involved in the 
binding of some BA derivatives in our recent publication46, and it also contacts the side chain of Leu266. Finally, 
the ureidic group of 10 forms water mediated interactions with Ser157, Gln158 on the extracellular loop (ECL) 
2, and Tyr240 on TM6. Our results indicate that along the MD simulation the ligand forms stable interactions 
with the residues Asn93, Glu169, Tyr240 and Leu266 (Fig. 4B). It is interesting to note that the same residues are 
involved in the binding of BA derivatives to GPBAR1 and showed to be relevant for its activation24,33,34,44,45. For 
the first time here we report that Asn93, Glu169, Tyr240 work as anchor point also for non-steroidal ligands and 
should be targeted in drug design of new GPBAR1 agonists.
Finally, we note that a few of the ligand/receptor contacts predicted by MD were not found by docking cal-
culations. This is due to the fact that the docking program neglects the presence of explicit water molecules and 
treats the protein as rigid, leading to a less accurate description of the ligand/receptor binding process. Based on 
our results, we suggest using more rigorous calculations that include an explicit solvent model and full receptor 
flexibility to disclose with accuracy the binding mode of non-steroidal GPBAR1 agonists.
Figure 3. (A) Dose response curves of compounds 9 and 10 (concentrations ranging from 1 to 50 µM) in 
luciferase reporter assay. (B) Real-time PCR analysis of mRNA expression of Pro-glucagon in GLUTag cells 
treated with compounds 9 and 10 at 10 μM, and TLCA used as a positive control (10 μM). Values are normalized 
to GAPDH and are expressed relative to those of not treated cells (NT) which are arbitrarily settled to 1. The 
relative mRNA expression is expressed as 2(−ΔΔCt). (C) Specificity of compounds 9 and 10 at 10 μM dose in 
luciferase reporter assays versus PPARα and PPARγ using Gemfibrozil (GEM, 10 μM) and Rosiglitazone (ROSI, 
100 nM) as positive controls respectively. (D) Specificity of compounds 9 and 10 at 10 μM in luciferase reporter 
assays versus LXRα and LXRβ using GW3965 (GW, 10 μM) as positive control. (E) Specificity of compounds 9 
and 10 at 10 μM in luciferase reporter assays versus FXR using CDCA (10 μM) as positive control; (F) Specificity 
of compounds 9 and 10 at 10 μM in luciferase reporter assays versus PXR using Rifaximin (Rifax, 10 μM) as 
positive control.
Compound R2
Aqueous 
solubility (μM) Log D
CIint (μL/min/
mg protein) t½ (min)
9 110 1.47 67 35
10 198 1.25 76 30
Table 2. In vitro pharmacokinetics for selected oxadiazole derivatives 9 and 10.
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Discussion
Among the BA receptors, GPBAR1 is considered a prominent target for the treatment of metabolic and inflam-
matory disorders. A selective modulation of this receptor is sought to avoid side effects due to over-activation 
of the signaling cascades controlled by other BA receptors. However, this task is challenging since BA receptors 
share similar structural requisites for ligand binding. In addition, most of the known ligands are BA derivatives 
that present the steroidal scaffold responsible for the promiscuous binding to the different BA receptors. In this 
background, the discovery of non-steroidal GPBAR1 agonists is of great demand, offering the opportunity to 
achieve a potent and selective modulation of the receptor.
In the present work we have pursued this goal combining computational, organic synthesis and pharmacolog-
ical techniques that led to the identification of ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl derivatives as new 
class of non-steroidal selective GPBAR1 agonists. The pharmacological characterization of these compounds 
shows high activity efficacy and selectivity towards GPBAR1 over the other BAs receptors as FXR, LXRα, LXRβ 
and PXR, and the related receptors PPARα and PPARγ. The most potent compounds of the series, 9 and 10, 
demonstrated to induce the expression of mRNA of the GPBAR1 target gene pro-glucagon in GLUTag cells, 
with compound 10 showing the same efficacy of TLCA used as GPBAR1 agonist reference compound. We have 
performed docking calculations and molecular dynamics simulations to disclose the binding mode of the most 
potent compound of the series, 10, showing that the ligand engages stable interactions with the receptor amino 
acids Asn93, Glu169, Tyr240 and Leu266. The same residues are involved in the binding of BA derivatives to 
GPBAR124,33,34,44,45, however this is the first time that they are found to be crucial also for the recognition of 
non-steroidal ligands. This unprecedented structural insight on ligand/receptor binding is valuable to guide fur-
ther drug design and lead optimization studies. Finally, the discovered ligands display optimal pharmacokinetic 
features such as suitable aqueous solubility and high microsomal stability. All together our findings prompt fur-
ther investigations on the ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl scaffold to achieve drug candidates for 
the treatment of GPBAR1 related disorders.
Methods
Chemistry. NMR spectra were performed on Varian Inova 400, 500 and 700 spectrometers (400 MHz, 500 
and 700 MHz for 1H and 100, 125 and 175 MHz for 13C, respectively). Residual signals of solvent were used as 
internal standards (δH 3.31 ppm and δC 49.0 ppm for CD3OD, δH 7.26 ppm and δC 77.0 ppm for CDCl3). Data 
for 1H NMR spectra are reported as chemical shift (δ, ppm), integration, molteplicity, coupling costant (Hz). 
Molteplicity of signals is given as singlet (s), broad singlet (br s), doplet (d), triplet (t), multiplet (m). Micromass 
Q-TOF mass spetcrometer was used to record high-resolution ESI-MS spectra.
The solvents and reagents were purchased from Sigma-Aldrich in ≥98% purity. All reactions were carried 
out under Ar atmosphere. Dichloromethane, ethyl ether and triethylamine were distilled from calcium hydride; 
methanol was dried from magnesium methoxide as previously reported31. The reaction were monitored with 
Alugram silica gel TLC plate, under UV light (254 and 365 nm). Column chromatography was performed on sil-
ica gel (200–400 mesh, from Macherey-Nagel Company). HPLC separations were performed using a Water Model 
510 pump, Waters Rheodine injector and Differential Refractormeter Model 401. Analytical HPLC analysis was 
used also to determine the purity of compounds (>95%), using a Nucleodur Sphinx RP column (Macherey-Nagel 
Company, 5 µm; 4.6 mm i.d.x250 mm, flow rate 1 mL/min) eluiting with the conditions reported for each individ-
ual compound in the supporting information.
Figure 4. (A) Binding mode of 10 (yellow sticks) to GPBAR1 (gray cartoon). Amino acids essential for ligand 
binding are depicted as sticks. Polar contacts are shown as dashed black lines. ECL1, residues 145–156 in 
ECL2, ECL3 and nonpolar hydrogens are undisplayed for clarity. (B) Interatomic distances (mean ± S.E.M.) 
representative of the main ligand/receptor contacts observed along the last 100 ns of MD simulations: (I) 
pyrrolidinyl ring (N)/Glu169 (Cδ), cyan bar; (II) pyrrolidinyl ring (N)/Asn93 (Cγ), orange bar; (III) phenyl 
(centroid)/Tyr240 (centroid of the phenolic ring), green bar; (IV) ureidic moiety (C)/Tyr (OH), gray bar; (V) 
cyclohexyl (centroid)/Leu266 (Cγ), yellow bar.
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Cell culture. HEK-293T and GLUTag cells were cultured and maintained at 37 °C and 5% CO2 in D-MEM 
additioned with 10% FBS, 1% glutamine and 1% penicillin/streptomycin.
Luciferase reporter gene assay and dose-response curves. Transactivation assay on HEK-293T cells 
was performed to investigate GPBAR1 activation, using compound 1–14 and TLCA as positive control at 10 µM, 
as previously reported47. EC50 of compounds 9 and 10 was evaluated treating HEK-293T cells transfected with 
increasing concentrations of two compounds (range from 1 to 50 µM).
The specificity of compounds 9 and 10 versus PPARα, PPARγ, LXRα, LXRβ, FXR and PXR was determined 
in luciferase reporter gene assays as previously reported29,31.
RNA isolation and RT-PCR. Evaluation of proglucagon mRNA expression was performed in RT-PCR 
on GLUTag cells (1 × 106 cells/well in a 6 well plate) as previously reported34,47. The relative mRNA expression 
was calculated and expressed as 2−(ΔΔCt). Forward and reverse primer sequences were the following: mouse 
GAPDH, ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mouse Pro-glucagon, tgaagacaaacgccactcac and 
caatgttgttccggttcctc.
LC-MS/MS ADME Methods. Chromatography was performed using a HPLC–MS system Q-ToF Premiere 
instrument (Waters, Co.) equipped with an ESI source and Waters pump systems. The mixture was separated on 
a Luna 5 µm C8(2) 100 °A 150 × 2 mm from Phenomenex. The mobile phase consisted of 0.2% formic acid (FA) 
in water as solvent A and 0.2% FA in acetonitrile as solvent B at a flow rate of 200 μL/min. The gradient was as 
follows: 0–2 min (75% A and 25% B), 2–20 min (5% A and 95% B), 20–30 min (75% A and 25% B). The detection 
of analytes was achieved by ESI in the positive mode with the appropriate MRM transition or by UV system at 
220 nm.
Solubility Measurements. Ten μL of a 10 mM solution in DMSO of the compound was diluted either in 
490 μL of PBS pH 7.4 or in the organic solvent MeOH (in triplicate). The tubes were gently shaken 24 h at room 
temperature, then centrifuged for 5 min at 4000 rpm. Ten μL of sample was diluted in 490 μL of MeOH. The solu-
bility is determined by the ratio of mass signal area PBS/organic solvent.
LogD Measurements. Ten μL of a 10 mM solution in DMSO of the compound was diluted in 490 μL of a 
1/1 octanol/PBS mixture at pH 7.4. The mixture was gently shaken for 2 h at room temperature. Ten microliters of 
each phase was diluted in 490 μL of MeOH and analyzed by LC-MS/MS. Each compound was tested in triplicate. 
Log D was determined as the logarithm of the ratio of concentration of product in octanol and PBS, determined 
by mass signals.
Microsomal Stability. Male mouse (CD-1) liver microsomes (Sigma-Aldrich) were used. All incubations 
were performed in duplicate in a shaking water bath at 37 °C. The incubation mixtures contained 1 μM compound 
with 1% DMSO used as a vehicle, mouse liver microsomes (0.3 mg of microsomal protein per mL), 5 mM MgCl2, 
1 mM NADP, 5 mM glucose 6-phosphate, 0.4 U·mL−1 glucose 6-phosphate dehydrogenase, and 50 mM potassium 
phosphate buffer (pH 7.4) in a final volume of 0.5 mL. Aliquots were removed at 0, 5, 10, 20, 30, and 40 min after 
microsome addition and the reaction was stopped by adding 200 μL of ice-cold acetonitrile. After 2 h, the samples 
were centrifuged for 10 min at 10000 rpm, and the supernatants were transferred in matrix tubes for LC-MS/MS 
analysis. Propranolol, known as a high hepatic clearance drug in rodents, was used as a quality-control compound 
for the microsomal incubations. The slope of the linear regression of the curve obtained reporting the natural 
logarithm of compound area versus incubation time (−k) was used in the conversion to in vitro t1/2 values by 
t1/2 = −ln(2)/k. In vitro intrinsic clearance (Clint expressed as μL/min/mg) was calculated according to the follow-
ing formula: Clint = volume of reaction (μL)/t1/2 (min)/protein of liver microsomes (mg).
Molecular docking. The Glide software package48 was used to perform molecular docking calculations of 10 
in the three-dimensional model of hGPBAR124. The ligand tridimensional structure was generated through the 
Maestro Build Panel49 and prepared for docking using LigPrep50. The ligand protonation states at pH 7.4 +/− 1.0 
were assigned using Epik51,52. The GPBAR1 model was instead prepared as described in our previous paper33. For 
grid generation a box of 25 × 25 × 25 Å centered on the binding cavity previously identified for bile acid ligands24 
was created. The Glide standard precision (SP) scoring function53,54 was used to score and rank the predicted 
binding poses. The twenty best ranked docking solutions were visually inspected.
Molecular dynamics. The predicted docking complexes were embedded in a 1-Palmitoyl-
2-oleoylphosphatidylcholine (POPC) phospholipids bilayer following a previously published protocol24. Each 
complex was then solvated according to the TIP3 water model through the solvation module of VMD 1.9.3. The 
ff14SB55, lipid1456 and gaff 57 Amber force fields were used to parameterize the protein, the lipids and the ligand, 
respectively. The addition of 12 Cl− ions ensured neutrality. Missing ligand charges and parameters were derived 
by means of the Antechamber program58, as described in a previous paper24. Each complex was then submitted to 
150 ns MD simulations with NAMD 2.1159, using the setup described in a previous publication24.
All of the pictures were rendered using PyMOL (www.pymol.org).
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